1. Home
  2. CTS vs SNDX Comparison

CTS vs SNDX Comparison

Compare CTS & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTS
  • SNDX
  • Stock Information
  • Founded
  • CTS 1896
  • SNDX 2005
  • Country
  • CTS United States
  • SNDX United States
  • Employees
  • CTS N/A
  • SNDX N/A
  • Industry
  • CTS Electrical Products
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTS Technology
  • SNDX Health Care
  • Exchange
  • CTS Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • CTS 1.2B
  • SNDX 1.3B
  • IPO Year
  • CTS N/A
  • SNDX 2016
  • Fundamental
  • Price
  • CTS $42.07
  • SNDX $13.82
  • Analyst Decision
  • CTS
  • SNDX Strong Buy
  • Analyst Count
  • CTS 0
  • SNDX 11
  • Target Price
  • CTS N/A
  • SNDX $38.55
  • AVG Volume (30 Days)
  • CTS 212.2K
  • SNDX 3.1M
  • Earning Date
  • CTS 10-28-2025
  • SNDX 10-31-2025
  • Dividend Yield
  • CTS 0.38%
  • SNDX N/A
  • EPS Growth
  • CTS 18.55
  • SNDX N/A
  • EPS
  • CTS 2.11
  • SNDX N/A
  • Revenue
  • CTS $520,937,000.00
  • SNDX $77,933,000.00
  • Revenue This Year
  • CTS $3.90
  • SNDX $641.22
  • Revenue Next Year
  • CTS $6.50
  • SNDX $110.64
  • P/E Ratio
  • CTS $19.97
  • SNDX N/A
  • Revenue Growth
  • CTS 1.12
  • SNDX 2126.66
  • 52 Week Low
  • CTS $34.02
  • SNDX $8.58
  • 52 Week High
  • CTS $59.68
  • SNDX $22.50
  • Technical
  • Relative Strength Index (RSI)
  • CTS 58.69
  • SNDX 36.78
  • Support Level
  • CTS $40.81
  • SNDX $14.08
  • Resistance Level
  • CTS $41.50
  • SNDX $15.93
  • Average True Range (ATR)
  • CTS 1.33
  • SNDX 1.03
  • MACD
  • CTS 0.46
  • SNDX -0.18
  • Stochastic Oscillator
  • CTS 85.95
  • SNDX 22.55

About CTS CTS Corporation

CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEM) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China; Singapore; the Czech Republic; Taiwan, Denmark, and other countries.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: